Anti-Rat CD4 (Clone OX-38) – Purified in vivo PLATINUM™ Functional Grade
Anti-Rat CD4 (Clone OX-38) – Purified in vivo PLATINUM™ Functional Grade
Product No.: C753
Clone OX-38 Target CD4 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names T-cell surface glycoprotein CD4, T-cell surface antigen T4/Leu-3, W3/25
antigen Isotype Mouse IgG2a Applications Depletion , ELISA , FA , FC , IP |
Antibody DetailsProduct DetailsReactive Species Rat Host Species Mouse Recommended Dilution Buffer Immunogen Lymphocytes or thymocyte glycoproteins Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? Depletion, ELISA, FA, FC, IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity OX-38 activity is directed against rat CD4. Background CD4 is a 55 kD single-chain type I transmembrane glycoprotein with four domains and is a
member of the Ig superfamily1,2. CD4 functions primarily as a coreceptor for the MHC class II
molecule-peptide complex and initiates the early phase of T-cell activation via its association
with the T-cell receptor complex and protein tyrosine kinase Lck3. In addition, CD4 T
lymphocytes are essential to the host response against infectious disease4 and CD4 T cells
mediate neuronal damage in infectious and immune-mediated diseases of the central nervous
system5. In macrophages and natural killer cells, CD4 plays a role in differentiation/activation,
cytokine expression and cell migration3. OX-38 was generated by immunizing mice with lymphocytes or thymocyte glycoproteins and subsequently fusing mouse spleen cells with the P3-X63/Ag 8 cell line6. OX-38 is a depleting monoclonal antibody used to study tolerance to allografts7,8,9,10,11 , Pneumocystis-host interaction4, and alopecia12 in rat models. Antigen Distribution CD4 is expressed on most thymocytes, a subset of T cells, and on
monocytes/macrophages. Ligand/Receptor LCK, PTK2/FAK1, P4HB/PDI, IL16, MHCII alpha and beta chains NCBI Gene Bank ID UniProt.org Research Area Adaptive Immunity . Immunology . Autoimmunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone OX-38 is a monoclonal antibody that specifically targets the rat CD4 antigen. While it is not commonly used in mice due to its specificity for rat CD4, its applications in rats can inform potential analogous uses in mice with species-specific CD4 antibodies. In rats, OX-38 is used for:
If a similar antibody were used in mice, such as one targeting mouse CD4 (e.g., YTS 177 clone), it could be applied for analogous purposes like:
However, specific applications for OX-38 in mice would not be directly relevant due to its rat-specificity. Based on the available search results, there is limited specific information about antibodies commonly used alongside OX-38 in experimental studies. However, the search results do provide some relevant context about related antibodies and the CD4 research landscape. Related CD4 AntibodiesThe W3/25 antibody is closely related to OX-38, as both antibodies bind to the same epitope on the CD4 antigen. This suggests that W3/25 would be used in similar experimental contexts, though they would compete for binding rather than being used simultaneously. In contrast, the OX-35 antibody recognizes a different epitope on CD4 than OX-38, which could make it suitable for use in combination experiments or for targeting different functional aspects of the CD4 molecule. Isotype ControlsFor flow cytometry applications using OX-38, researchers commonly employ appropriate isotype controls. The Mouse IgG2a, κ isotype control is specifically recommended for use with OX-38, as it matches the antibody's isotype. This control is essential for determining background staining levels and ensuring accurate interpretation of flow cytometry data. Functional ContextOX-38 is primarily used to identify and deplete CD4-expressing cells, including T helper cells, monocytes, and macrophages in rat models. Given its role in studying immune responses, it would likely be used alongside other T cell markers and immune cell antibodies, though the specific combinations are not detailed in the available literature. The search results indicate that while OX-38 is well-characterized for its binding properties and applications, comprehensive information about commonly paired antibodies in published studies is not readily available in these sources. Clone OX-38 is a mouse monoclonal antibody targeting rat CD4, cited extensively in immunological research primarily for its role in depleting or detecting CD4 T cells in rat models. The key findings from scientific literature that cite clone OX-38 are:
In summary, the antibody clone OX-38 is a key reagent for studying the function and dynamics of CD4+ T cells in rat models through depletion or detection, with its unique epitope specificity making it valuable for research requiring precise targeting of the CD4 molecule. Dosing regimens for clone OX-38 (a rat anti-mouse CD4 monoclonal antibody) can vary across different mouse models based on factors such as the experimental aim (e.g., immune cell depletion vs. functional blocking), mouse strain, and disease context. However, detailed peer-reviewed dosing references specifically for OX-38 are limited in the provided results; the search produced more data on other monoclonal antibodies, such as anti-CD3, anti-PD-1, and OX-86 (anti-CD134). Key context and supporting details:
Points to consider for OX-38 in different mouse models:
If you require dosing for a specific disease model or experimental goal, searching for peer-reviewed literature referencing OX-38 in that precise context is advisable. When in doubt, start with established dosing (e.g., 200–500 μg i.p. every 3–7 days) and monitor for efficacy and toxicity, adjusting based on observed effects and study needs. Summary table for context:
*Estimated for OX-38 based on similar antibodies; confirm in pilot studies or relevant literature. If you need precise, model-specific OX-38 regimens, direct primary references will yield the most reliable dosing information. References & Citations1. Lynch GW, Turville S, Carter B, et al. Immunol Cell Biol. 84(2):154-165. 2006. 2. Wittlich M, Thiagarajan P, Koenig BW, et al. Biochim Biophys Acta. 1798(2):122-127. 2010. 3. https://www.uniprot.org/uniprotkb/P05540/entry 4. Thullen TD, Ashbaugh AD, Daly KR, et al. Infect Immun. 71(11):6292-6297. 2003. 5. Brunn A, Utermöhlen O, Carstov M, et al. Am J Pathol. 173(1):93-105. 2008. 6. Jefferies WA, Green JR, Williams AF. J Exp Med. 162(1):117-127. 1985. 7. Flavin T, Shizuru J, Seydel K, et al. J Heart Transplant. 9(5):482-488. 1990. 8. Arima T, Lehmann M, Flye MW. Transplantation. 63(2):284-292. 1997. 9. Motoyama K, Arima T, Lehmann M, et al. Surgery. 122(2):213-219. 1997. 10. Qi Z, Riesbeck K, Ostraat O, et al. Transpl Immunol. 5(3):204-211. 1997. 11. Shizuru JA, Seydel KB, Flavin TF, et al. Transplantation. 50(3):366-373. 1990. 12. McElwee KJ, Spiers EM, Oliver RF. Br J Dermatol. 140(3):432-437. 1999. Technical ProtocolsCertificate of Analysis |
Formats Available
